João Henrique Lima Feldmann

João Henrique Lima Feldmann

Auto-generated profile, based on publicly available information

João Henrique Lima Feldmann

Departamento de Oncologia Clínica, Hospital Sírio-Libanês, São Paulo, SP, Brasil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2025 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
JFJoão Felipe Lima Feldmann
João Felipe Lima Feldmann
JFJoão Henrique Lima Feldmann
João Henrique Lima Feldmann
MAMayara Lopes Araujo
Mayara Lopes Araujo
MGMariana Carvalho Gouveia
Mariana Carvalho Gouveia
MSMariana Scaranti
Mariana Scaranti

1 January 2026 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
JFJoão Henrique Feldmann
João Henrique Feldmann
JFJoão Felipe Feldmann
João Felipe Feldmann
CFCassio Murilo Trovo Hidalgo Filho
Cassio Murilo Trovo Hidalgo Filho
GAGustavo Luis Contado Alves
Gustavo Luis Contado Alves
RVRafael Sarlo Vilela
Rafael Sarlo Vilela
GJGilberto de Castro Júnior
Gilberto de Castro Júnior
Poorly differentiated thyroid carcinoma (PDTC) is a rare and aggressive malignancy with a poor prognosis. Immunotherapy is typically guided by agnostic biomarkers such as microsatellite instability-high or high tumor mutational burden (TMB); however, these biomarkers are uncommon in PDTC. Therefore, identifying alternative predictive biomarkers remains an urgent necessity. We report the case of a 71-year-old woman who presented with life-threatening locoregional disease and was ineligible for radioiodine or tyrosine kinase inhibitors due to a prior subarachnoid hemorrhage. Molecular profiling [...] ABSTRACT Poorly differentiated thyroid carcinoma (PDTC) is a rare and aggressive malignancy with a poor prognosis. Immunotherapy is typically guided by agnostic biomarkers such as microsatellite instability-high or high tumor mutational burden (TMB); however, these biomarkers are uncommon in PDTC. Therefore, identifying alternative predictive biomarkers remains an urgent necessity. We report the case of a 71-year-old woman who presented with life-threatening locoregional disease and was ineligible for radioiodine or tyrosine kinase inhibitors due to a prior subarachnoid hemorrhage. Molecular profiling